Accuray (ARAY) Getting Somewhat Favorable News Coverage, Analysis Finds

Media headlines about Accuray (NASDAQ:ARAY) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accuray earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.0593119557878 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Several brokerages recently commented on ARAY. BidaskClub cut shares of Accuray from a “hold” rating to a “sell” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a research note on Tuesday, February 27th. Finally, Royal Bank of Canada set a $6.00 price objective on shares of Accuray and gave the company a “hold” rating in a research note on Wednesday, January 24th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $7.21.

Shares of NASDAQ ARAY opened at $4.70 on Friday. The company has a current ratio of 1.54, a quick ratio of 0.99 and a debt-to-equity ratio of 2.66. Accuray has a 52 week low of $3.60 and a 52 week high of $6.15.

Accuray (NASDAQ:ARAY) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.05. Accuray had a negative net margin of 6.09% and a negative return on equity of 44.66%. The firm had revenue of $100.33 million during the quarter, compared to the consensus estimate of $90.31 million. During the same period last year, the firm posted ($0.11) EPS. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. sell-side analysts predict that Accuray will post -0.19 EPS for the current year.

In other Accuray news, CEO Joshua Levine sold 8,675 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $4.65, for a total transaction of $40,338.75. Following the completion of the transaction, the chief executive officer now directly owns 1,426,753 shares in the company, valued at approximately $6,634,401.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 14,257 shares of company stock valued at $66,295 over the last 90 days. 3.90% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3340266/accuray-aray-getting-somewhat-favorable-news-coverage-analysis-finds.html.

Accuray Company Profile

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Incyte  Given a $65.00 Price Target at Oppenheimer
Incyte Given a $65.00 Price Target at Oppenheimer
NewLink Genetics  Downgraded by Robert W. Baird
NewLink Genetics Downgraded by Robert W. Baird
Tractor Supply’s  “Neutral” Rating Reaffirmed at Wedbush
Tractor Supply’s “Neutral” Rating Reaffirmed at Wedbush
Bridgewater Bancshares  Earns Buy Rating from Analysts at Sandler O’Neill
Bridgewater Bancshares Earns Buy Rating from Analysts at Sandler O’Neill
Cantor Fitzgerald Reiterates $17.00 Price Target for Verastem
Cantor Fitzgerald Reiterates $17.00 Price Target for Verastem
Incyte  PT Lowered to $96.00
Incyte PT Lowered to $96.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.